# Tislelizumab in Addition to BACE in Patients with NSCLC

> **NCT05058560** · PHASE2 · COMPLETED · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 30 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05058560
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2025-02-04
- **Final completion:** 2025-02-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05058560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05058560, "Tislelizumab in Addition to BACE in Patients with NSCLC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05058560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*